| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | 
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Total Revenue | 236.08B | 232.41B | 195.47B | 172.37B | 151.10B | 144.03B | 
| Gross Profit | 168.66B | 167.03B | 131.54B | 107.67B | 94.24B | 94.60B | 
| EBITDA | 66.99B | 68.30B | 52.57B | 35.34B | 31.70B | 34.15B | 
| Net Income | 45.72B | 45.26B | 38.59B | 19.60B | 44.87B | 21.34B | 
| Balance Sheet | ||||||
| Total Assets | 0.00 | 372.02B | 292.81B | 257.56B | 277.95B | 238.85B | 
| Cash, Cash Equivalents and Short-Term Investments | 56.37B | 78.08B | 13.58B | 11.92B | 35.05B | 11.27B | 
| Total Debt | 0.00 | 32.13B | 8.04B | 11.95B | 42.21B | 46.08B | 
| Total Liabilities | -263.58B | 108.43B | 71.79B | 60.68B | 87.42B | 89.55B | 
| Stockholders Equity | 263.58B | 239.53B | 198.29B | 175.16B | 170.00B | 129.92B | 
| Cash Flow | ||||||
| Free Cash Flow | 0.00 | 50.64B | 23.21B | 16.58B | 9.02B | 24.39B | 
| Operating Cash Flow | 0.00 | 67.77B | 32.28B | 26.89B | 21.04B | 32.93B | 
| Investing Cash Flow | 0.00 | -83.72B | -14.75B | 11.71B | -10.00B | -7.22B | 
| Financing Cash Flow | 0.00 | 20.14B | -17.79B | -44.00B | -8.68B | -25.49B | 
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth | 
|---|---|---|---|---|---|---|---|
| ― | ₹1.05T | 18.44 | ― | 0.64% | 14.10% | 9.72% | |
| ― | ₹1.27T | 23.63 | ― | 0.83% | 6.40% | 25.27% | |
| ― | ₹893.78B | 23.70 | ― | 0.61% | 12.40% | 63.16% | |
| ― | ₹993.45B | 21.73 | ― | 1.10% | 14.52% | 9.46% | |
| ― | ₹1.22T | 60.49 | ― | 0.89% | 7.63% | 15.39% | |
| ― | ₹1.02T | 53.21 | ― | 0.04% | 21.66% | -4.92% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | 
Zydus Lifesciences Limited has completed the acquisition of Amplitude Surgical SA, France, through its wholly owned subsidiary, Zydus MedTech France SAS. With the acquisition of the remaining 14.4% of shares, Zydus MedTech France now fully owns Amplitude Surgical, enhancing its strategic positioning in the medical technology sector. This acquisition signifies Zydus’s commitment to expanding its footprint in the European market and strengthening its portfolio in the medical devices industry.
Zydus Lifesciences Limited has received approval from Health Canada for its generic Mesalamine suppositories, used in the treatment of mildly to moderately active ulcerative proctitis. This approval is expected to enhance Zydus’s market presence in Canada, where the product had annual sales of 4.86 million CAD, and it will be manufactured at their facility in Ahmedabad, India.
Zydus Lifesciences Limited has announced the loss of a share certificate belonging to one of its shareholders, as published in the Financial Express. The company has issued a notice that it will issue a duplicate share certificate if no objections are received within seven days, advising the public to refrain from dealing with the lost certificate.
Zydus Lifesciences Limited has announced that it received an Establishment Inspection Report (EIR) from the USFDA for its oncology injectable facility in SEZ1, Ahmedabad. The facility’s classification has been upgraded from Official Action Indicated (OAI) to Voluntary Action Indicated (VAI), reflecting improvements in compliance and potentially enhancing the company’s reputation and operational capabilities in the pharmaceutical industry.
Zydus Lifesciences Ltd., through its subsidiary Zydus Lifesciences Global FZE, has entered into an exclusive licensing and supply agreement with Synthon BV for the generic version of Ozanimod Capsules, targeting the U.S. market. This collaboration allows Zydus to commercialize the product in the U.S., while Synthon will handle regulatory approval and manufacturing. The agreement positions Zydus to enhance its presence in the U.S. pharmaceutical market, particularly in the treatment of multiple sclerosis and ulcerative colitis, and reflects its strategic focus on expanding access to essential medicines.